



One Broadway, 14th Floor • Cambridge, MA 02142 • 617-583-1315 • [www.invivotherapeutics.com](http://www.invivotherapeutics.com)

May 18, 2009

**Contacts:**

Frank Reynolds 617-475-1518  
[publicrelations@invivotherapeutics.com](mailto:publicrelations@invivotherapeutics.com)

**For Immediate Release:**

***InVivo Therapeutics CEO Frank Reynolds Nominated as 'CEO of the Year'***

Cambridge, MA--- InVivo Therapeutics President and CEO Frank Reynolds has received several nominations for the Massachusetts Technology Leadership Council 'CEO of the Year' award. As a nominee for a 2009 Mass Technology Leadership Award, Reynolds is being recognized as one of the strongest leaders in the Massachusetts technology community.

The awards, which fall into several categories, are given out every year, and are presented to both companies and individuals who "epitomize leadership and excellence in business and technology." They are also one of a kind, as they are the "first and only awards to equally recognize outstanding achievement in the development and implementation of technology."

The nominations come as a pleasant surprise to Reynolds. "It is humbling to be recognized by my peers and I deeply appreciate the recognition associated with this award" he says. "There is no doubt that I accept this nomination on behalf of my entire team who work diligently on a daily basis to bring technology to market that can significantly impact the life of a spinal cord injury patient."

This year marks the 12th anniversary of the Annual Awards Program for the Mass Technology Leadership Council. Finalists will be selected during the months of June and July, and the award winners will be announced on November 5, 2009 at the formal Awards Gala.

\*

*InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, PhD, of the Massachusetts Institute of Technology, Jay Vacanti, MD, of the Massachusetts General and Children's Hospitals in Boston, and Yang Teng, PhD, MD, of Harvard's Brigham and Women's Hospital.*